Lycotec

Lycotec is a private UK biotechnology and health company based in the Cambridge area that develops carotenoid- and lycosome-based technologies spanning pharmaceuticals, diagnostics, nutraceuticals, and functional foods. The company positions itself around targeted delivery, bioavailability enhancement, and oxygenation/inflammation-focused health products, with applications in cardiometabolic disease, liver disease, aging, and nutrition. Its website highlights proprietary liver-targeting oral delivery technology, including LycoStatin, and a broader Lycopharma offering. Publicly visible clinical activity appears limited and early, with company materials referencing clinical studies in overweight volunteers and nonalcoholic steatohepatitis, and a stated plan to pursue a Phase 2 trial targeting cholesterol crystals in vulnerable plaques. Overall, Lycotec appears to be a small, platform-oriented translational biotech/nutrition company rather than a conventional later-stage drug developer.